Christopher A. Yasenchak, MD, discusses brentuximab vedotin (Adcetris) plus nivolumab (Opdivo) in patients with Hodgkin lymphoma.
Christopher A. Yasenchak, MD, associate chair of Hematology Research, Willamette Valley Cancer Institute and Research Center/US Oncology Research, discusses brentuximab vedotin (Adcetris) plus nivolumab (Opdivo) in patients with Hodgkin lymphoma.
The phase II study treated patients ≥60 years old who are ineligible or declined from conventional therapy. Patients also could not have had received prior therapy. The frontline study treated patients with a combination of brentuximab vedotin and nivolumab every 3 weeks up to 16 cycles.
Based on the 18 evaluable subjects, the overall response rate was 100%, with a 72% complete response rate. The data from the study suggests that brentuximab vedotin in combination with nivolumab is a promising treatment for patients with Hodgkin lymphoma and it appears well tolerated in the patients who participated in the trial.